Payment overview · 2025
General Payments
$1,154.50
52 reported records · 13 companies
Healthcare provider profile · identity verified
Nick M Pham, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FALLS CHURCH, VA · NPI 1801082508
Verified facts
What the public records show
CMS Open Payments records show Nick M Pham, M.D. received $1,154.50 in general payments during 2025 across 52 reported records.
Gilead Sciences, Inc. accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Ozempic, Prolia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vemlidy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $228.65 | 19.8% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $202.55 | 17.5% | 10 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $128.47 | 11.1% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $124.26 | 10.8% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $120.71 | 10.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $100.44 | 8.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $96.59 | 8.4% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.80 | 4.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.33 | 1.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.57 | 1.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.60 | 1.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.26 | 1.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.27 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,154.50 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $147.74 | 7 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $128.47 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $86.13 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $78.44 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $74.60 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $67.54 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $58.27 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.11 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.76 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $38.32 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $27.68 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $27.13 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 123 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 38 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 118 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | 14 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
118 | 72 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
123 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1277 | 373 |
| Losartan Potassium | Losartan Potassium | 753 | 220 |
| Metformin Hcl | Metformin Hcl | 587 | 180 |
| Amlodipine Besylate | Amlodipine Besylate | 543 | 169 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 347 | 102 |
| Lisinopril | Lisinopril | 326 | 100 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 304 | 170 |
| Metoprolol Succinate | Metoprolol Succinate | 267 | 77 |
| Omeprazole | Omeprazole | 227 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 184 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 170 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 58 |
| Januvia | Sitagliptin Phosphate | 145 | 33 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 138 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 136 | 40 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 127 | 89 |
| Farxiga | Dapagliflozin Propanediol | 123 | 33 |
| Prolia | Denosumab | 118 | 72 |
| Simvastatin | Simvastatin | 113 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 112 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 101 | 37 |
| Azelastine Hcl | Azelastine Hcl | 100 | 46 |
| Celecoxib | Celecoxib | 100 | 54 |
| Montelukast Sodium | Montelukast Sodium | 85 | 29 |
| Azithromycin | Azithromycin | 84 | 76 |
| Chlorthalidone | Chlorthalidone | 81 | 27 |
| Meloxicam | Meloxicam | 80 | 65 |
| Allopurinol | Allopurinol | 78 | 29 |
| Carvedilol | Carvedilol | 76 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 72 | 27 |
| Famotidine | Famotidine | 71 | 25 |
| Atenolol | Atenolol | 69 | 19 |
| Meclizine Hcl | Meclizine Hcl | 68 | 45 |
| Fenofibrate | Fenofibrate Nanocrystallized | 67 | 29 |
| Prednisone | Prednisone | 64 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 36 |
| Gabapentin | Gabapentin | 61 | 31 |
| Alendronate Sodium | Alendronate Sodium | 60 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 33 |
| Eliquis | Apixaban | 56 | 12 |
| Valsartan | Valsartan | 55 | 16 |
| Glipizide | Glipizide | 52 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 42 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 49 | 34 |
| Glimepiride | Glimepiride | 47 | 15 |
| Furosemide | Furosemide | 44 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 15 |
| Vascepa | Icosapent Ethyl | 42 | suppressed |
| Lidocaine | Lidocaine | 41 | 17 |
| Ezetimibe | Ezetimibe | 40 | 11 |
| Finasteride | Finasteride | 40 | 18 |
| Linzess | Linaclotide | 38 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 36 | 30 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 36 | 12 |
| Colchicine | Colchicine | 35 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 34 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Irbesartan | Irbesartan | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 11 |
| Tradjenta | Linagliptin | 33 | suppressed |
| Dutasteride | Dutasteride | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Jardiance | Empagliflozin | 29 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 28 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 27 | suppressed |
| Methimazole | Methimazole | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 25 | 25 |
| Vemlidy | Tenofovir Alafenamide | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 16 |
| Candesartan Cilexetil | Candesartan Cilexetil | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 20 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 20 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 13 |
| Fluocinonide | Fluocinonide | 18 | 13 |
| Ibuprofen | Ibuprofen | 18 | 13 |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Naproxen | Naproxen | 16 | 14 |
| Calcitriol | Calcitriol | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 11 |
| Glipizide Er | Glipizide | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Pregabalin | Pregabalin | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,154.50 · 52 records | Gilead Sciences, Inc. | AIRSUPRA, BREZTRI, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, LINZESS, MOUNJARO, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, YUPELRI, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error